Follow-Up Approach for Patients with Initial BPH Diagnosis

Initial Evaluation Components

The American Urological Association recommends using the AUA Symptom Index as the primary symptom-scoring instrument in the initial assessment and subsequent follow-up visits 1, 2
Medical history, physical examination, and urinalysis are mandatory components of the initial evaluation, according to the American Urological Association 1, 3
Serum PSA testing is recommended for patients with a life expectancy >10 years and when knowledge of prostate cancer would change management, as suggested by the American Urological Association 3

The first follow-up visit for patients on alpha blockers, PDE5 inhibitors, anticholinergics, and beta-3 agonists should be 4-12 weeks after initiation, as recommended by the American Urological Association 1, 4
For 5-alpha reductase inhibitors, the first follow-up visit should be 3-6 months after initiation due to longer onset of action, according to the American Urological Association 4
Assessment at follow-up visits should include the IPSS questionnaire to evaluate symptom changes, as suggested by the American Urological Association 4, 2
Evaluation of medication side effects, quality of life assessment, and optional post-void residual measurement and uroflowmetry should also be included in follow-up visits, as recommended by the American Urological Association 4, 5

If symptoms improve and side effects are tolerable, the American Urological Association recommends continuing current therapy with annual follow-up 4
If symptoms do not improve or side effects are intolerable, consideration should be given to changing medical management or surgical intervention, as suggested by the American Urological Association 1, 4

Symptom score changes and the degree of bother should be the primary determinants of treatment response or disease progression, according to the American Urological Association 2
BPH can be progressive, with prevalence of moderate-to-severe LUTS rising to nearly 50% by age 80, as reported by the American Urological Association 1, 6
The risk of acute urinary retention increases with age, from 6.8 episodes per 1,000 patient years overall to 34.7 episodes in men aged 70 and older, as noted by the American Urological Association 1

Failing to reassess symptoms with a validated tool like IPSS at follow-up visits is a common pitfall, as warned by the American Urological Association 1, 2
Not considering prostate size when evaluating treatment response, and overlooking the need for longer follow-up periods when evaluating 5ARI efficacy, are also common pitfalls, as noted by the American Urological Association 1, 4
Neglecting to assess for complications of BPH that may require more urgent intervention is another common pitfall, as warned by the American Urological Association 4

The American Urological Association (AUA) recommends that the initial evaluation of patients with suspected BPH and LUTS include the International Prostate Symptom Score (IPSS) to quantify symptom severity. 7
A thorough medical history covering onset, duration, and severity of lower urinary tract symptoms is required in the initial work‑up. 7, 8
A physical examination with digital rectal examination (DRE) to assess prostate size and characteristics is mandatory for all patients being evaluated for BPH. 7, 8
Urinalysis is mandated to screen for infection, hematuria, or other urinary‑tract pathology during the initial assessment. 7, 8

Serum PSA testing is recommended for patients with a life expectancy > 10 years when the result could influence management (e.g., suspicion of prostate cancer). 8

Routine abdominal CT scanning is not part of the standard initial evaluation for BPH; imaging is reserved for cases where history, exam, or urinalysis suggest renal disease, urinary retention, or complications. 7
Baseline serum creatinine measurement is not routinely recommended because clinically significant renal insufficiency attributable to BPH occurs in < 1 % of patients. 7
Routine cystoscopy is not recommended as part of the initial BPH assessment; it may be considered only when initial findings suggest a non‑prostatic cause of symptoms or when an invasive therapeutic approach is being contemplated. 7, 8
Prostate biopsy is not included in the initial evaluation of BPH; it is indicated only when PSA is abnormal or DRE findings raise suspicion for prostate cancer. 8

The IPSS classifies symptom severity as mild (0‑7), moderate (8‑19), or severe (20‑35), providing a standardized metric for BPH symptom burden. 7
Compared with an unstructured interview, the IPSS offers superior documentation of baseline urinary symptoms, facilitating consistent follow‑up. 7
The AUA recommends using IPSS scores, together with patient‑reported bother, to guide treatment decisions, with higher scores generally prompting pharmacologic or surgical interventions. 7
Serial IPSS assessments enable monitoring of treatment response and detection of symptom progression in patients managed conservatively. 7

The AUA cautions that symptom scores alone should not dictate intervention; the degree of bother experienced by the patient is a critical factor in management decisions. 7